There is not a big cost difference between a Nasdaq listing and a OTC listing. Eventually Laidlaw "maybe" in a position to uplist, but that is a long ways off. They are in no position right now to meet the higher reporting requirements for a Nasdaq listing. If Laidlaw wanted to do a R/S and uplist to the Nasdaq they might be able to meet the initial requirements, however continuing to meet the listing requirements of Nasdaq afterwards is entirely another story. There would be many benefits to uplisting to the Nasdaq down the road, however being that Laidlaw is only in it's infancy right now, and void of revenue, uplisting would be neither economical nor possible given the financial state of the company right now. Take a look at what Laidlaw would have to do to continue being listed on Nasdaq, and then tell me they could meet those requirements. Not right now!